Femasys Inc (FEMY) Stock Price, Quote & News

Company Profile

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-genera...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 770 500 3910

Fax: 404 581 5903

Website: www.femasys.com

Address:

3950 Johns Creek Court, Suite 100, Suwanee, United States

steve04240 Mar. 20 at 10:50 PM

$FEMY I wonder why Silverman resigned

1 · Reply

Ked1977 Mar. 20 at 10:32 PM

$FEMY FEMY’s 8-K filing today looks suspicious to me. Filing a lender-friendly amendment and issuing 16.38 million new $0.58 warrants right before earnings does not exactly inspire confidence. It doesn’t guarantee the report will be bad, but it feels like management wanted to clean up financing issues before the market sees the numbers. That makes it look defensive, dilutive, and more beneficial to lenders than common shareholders.

1 · Reply

Mirto Mar. 20 at 8:20 PM

$FEMY market is telling everyone that Kathy Septic sucks. More bloated overhead and free shares for her dolts on the “board”. No sales.

1 · Reply

Ked1977 Mar. 20 at 5:20 PM

$FEMY would love to know everyone’s thoughts on what the earnings report will bring next week.

1 · Reply

ZeroJobZeroProblem Mar. 20 at 3:07 PM

$FEMY

1 · Reply

David_M_ Mar. 20 at 1:42 PM

$FEMY

0 · Reply

steve04240 Mar. 20 at 11:37 AM

$FEMY pretty strong resistance up ahead we need some news so we can blast through

0 · Reply

FastRocketTraders Mar. 19 at 10:44 PM

$FEMY

0 · Reply

TripTrap Mar. 19 at 4:09 PM

$FEMY Okay…so much for just finding support at the breakout and heading north again. What it has done though is find support at Monday’s gap opening, filling it in… Let’s hope price can hold here. What’s good is we still have a nice breakaway gap in our back pocket down at .5360. Also, we still have that nice flat area up at .6299 that we will take out. Just have to wait it out…

1 · Reply

David_M_ Mar. 19 at 1:20 PM

$FEMY

0 · Reply

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 23, 2026, 9:00 AM EST - 26 days ago

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Jan 13, 2026, 9:00 AM EST - 2 months ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Dec 18, 2025, 9:15 AM EST - 3 months ago

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Nov 25, 2025, 9:15 AM EST - 4 months ago

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PMCB

Nov 3, 2025, 8:30 AM EST - 4 months ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Oct 16, 2025, 9:00 AM EDT - 5 months ago

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Sep 11, 2025, 9:00 AM EDT - 6 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

Sep 8, 2025, 9:00 AM EDT - 6 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

Aug 25, 2025, 11:44 PM EDT - 7 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

Aug 8, 2025, 4:05 PM EDT - 8 months ago

Femasys Announces Second Quarter Financial Results for 2025

Aug 6, 2025, 9:00 AM EDT - 8 months ago

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

Jul 1, 2025, 9:00 AM EDT - 9 months ago

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Jun 25, 2025, 9:00 AM EDT - 9 months ago

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Jun 17, 2025, 9:00 AM EDT - 9 months ago

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Jun 11, 2025, 9:00 AM EDT - 10 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

May 29, 2025, 4:23 PM EDT - 10 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 8, 2025, 5:01 PM EDT - 11 months ago

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Mar 19, 2025, 9:20 AM EDT - 1 year ago

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Mar 18, 2025, 9:00 AM EDT - 1 year ago

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

Feb 25, 2025, 9:20 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Feb 11, 2025, 9:00 AM EST - 1 year ago

Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Jan 30, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

Jan 16, 2025, 8:30 AM EST - 1 year ago

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

Nov 26, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment

Nov 12, 2024, 8:30 AM EST - 1 year ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Infertility Clinic Customers from Coast to Coast

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

May 17, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

May 16, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council

May 9, 2024, 8:30 AM EDT - 2 years ago

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 2 years ago

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

Apr 18, 2024, 8:30 AM EDT - 2 years ago

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Mar 20, 2024, 8:15 AM EDT - 2 years ago

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Mar 6, 2024, 9:00 AM EST - 2 years ago

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Feb 28, 2024, 9:00 AM EST - 2 years ago

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

steve04240 Mar. 20 at 10:50 PM

$FEMY I wonder why Silverman resigned

1 · Reply

Ked1977 Mar. 20 at 10:32 PM

1 · Reply

Mirto Mar. 20 at 8:20 PM

$FEMY market is telling everyone that Kathy Septic sucks. More bloated overhead and free shares for her dolts on the “board”. No sales.

1 · Reply

Ked1977 Mar. 20 at 5:20 PM

$FEMY would love to know everyone’s thoughts on what the earnings report will bring next week.

1 · Reply

ZeroJobZeroProblem Mar. 20 at 3:07 PM

$FEMY

1 · Reply

David_M_ Mar. 20 at 1:42 PM

$FEMY

0 · Reply

steve04240 Mar. 20 at 11:37 AM

$FEMY pretty strong resistance up ahead we need some news so we can blast through

0 · Reply

FastRocketTraders Mar. 19 at 10:44 PM

$FEMY

0 · Reply

TripTrap Mar. 19 at 4:09 PM

1 · Reply

David_M_ Mar. 19 at 1:20 PM

$FEMY

0 · Reply

dtonme Mar. 18 at 8:23 PM

$FEMY This is what I am noticing about FEMY; it seems to have a pretty good support/resistance line at .58, it is in a long term downtrend since March 2024, it is in a short term uptrend being supported by the support/resistance line which goes back to last October 2025, it is making higher lows and higher highs in the past 5 weeks or so. This is all just observations and doesn't promise anything going forward. Just putting it out there for those following charts

1 · Reply

dtonme Mar. 18 at 8:13 PM

$FEMY

0 · Reply

harambe_reborn Mar. 18 at 8:11 PM

$FEMY Beaumont Hospitals are some of the premier facilities in the state of Michigan, they have broad reach and big $$$ the Dr also works in Oakland county which is the wealthiest county in the entire state could we get a PR soon w/ partnerships involving Michigan based providers??

0 · Reply

IamFullBull Mar. 18 at 8:09 PM

$FEMY Patient pays.

0 · Reply

TripTrap Mar. 18 at 2:16 PM

$FEMY You don't bring someone onto the board like this with these credentials for nothing - They've got plans!! Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School. “As we continue advancing innovative solutions in women’s health, Dr. Eichenbaum brings a unique combination of clinical and technical expertise, along with deep financial insight, that will be invaluable to Femasys,” said Kathy Lee-Sepsick, Founder and CEO.

1 · Reply

DoyleStockkks Mar. 18 at 1:23 PM

$FEMY

0 · Reply

steve04240 Mar. 18 at 11:52 AM

$FEMY a little premarket L2 look

1 · Reply

Bluesir Mar. 18 at 10:30 AM

$FEMY I miss those days with +20/30%. Last time was last November, the 5th and the 7th. I think now it right time for them! 🤪

1 · Reply

Ked1977 Mar. 17 at 6:35 PM

$FEMY it’s going down because I took the chance to buy more to average down. I should have known better. I continue to loose faith in this stock.

5 · Reply

4RiskyBusiness4 Mar. 17 at 5:34 PM

$FEMY Hope you secured your position.

0 · Reply

TripTrap Mar. 17 at 2:24 PM

$FEMY After yesterday’s price surge, we are simply coming back down and testing the breakout around $.5900. - very normal price action. We also know today is a temporary retracement as yesterday‘s high and today’s high so far are both at .6299 creating a flat shelf up there that will absolutely be taken out to the upside… Maybe not today, but soon! Bullish AF 💪🔥

1 · Reply

ook__ Mar. 17 at 1:41 PM

$FEMY PUMP PUMP PUMP

2 · Reply

Market Cap	32.60M
Revenue (ttm)	1.63M
Net Income (ttm)	-18.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,154.60%
Debt to Equity Ratio	0.02

Volume	744,900
Avg Vol	719,122
Day's Range	N/A - N/A
Shares Out	58.48M
Stochastic %K	35%
Beta	-2.53
Analysts	Strong Sell
Price Target	$3.50